• Publications
  • Influence
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
TLDR
Cell line experiments suggest that the androgen-responsive promoter elements of TMPRSS2 mediate the overexpression of ETS family members in prostate cancer. Expand
The landscape of somatic copy-number alteration across human cancers
TLDR
It is demonstrated that cancer cells containing amplifications surrounding the MCL1 and BCL2L1 anti-apoptotic genes depend on the expression of these genes for survival, and a large majority of SCNAs identified in individual cancer types are present in several cancer types. Expand
The polycomb group protein EZH2 is involved in progression of prostate cancer
TLDR
Dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression. Expand
Integrative Clinical Genomics of Advanced Prostate Cancer
TLDR
This cohort study provides clinically actionable information that could impact treatment decisions for affected individuals and identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF. Expand
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
TLDR
A systematic method, called Genomic Identification of Significant Targets in Cancer (GISTIC), designed for analyzing chromosomal aberrations in cancer, is used to study gliomas and the results support the feasibility and utility of systematic characterization of the cancer genome. Expand
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
TLDR
It is suggested that MITF represents a distinct class of ‘ lineage survival’ or ‘lineage addiction’ oncogenes required for both tissue-specific cancer development and tumour progression, and Targeting MITF in combination with BRAF or cyclin-dependent kinase inhibitors may offer a rational therapeutic avenue into melanoma, a highly chemotherapy-resistant neoplasm. Expand
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
TLDR
SPOP mutations may define a new molecular subtype of prostate cancer, with mutations involving the SPOP substrate-binding cleft in 6–15% of tumors across multiple independent cohorts. Expand
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
TLDR
Enhanced intracellular conversion of adrenal androgens to testosterone and dihydrotestosterone is a mechanism by which prostate cancer cells adapt to androgen deprivation and suggest new therapeutic targets. Expand
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
TLDR
The role of AR in androgen-independent cancer cells is not to direct the androgen -dependent gene expression program without androgen, but rather to execute a distinct program resulting in androgens-independent growth. Expand
Delineation of prognostic biomarkers in prostate cancer
TLDR
Two genes—hepsin, a transmembrane serine protease, and pim-1, a serine/threonine kinase—are assessed at the protein level using tissue microarrays consisting of over 700 clinically stratified prostate-cancer specimens and linked clinical and pathology data are established. Expand
...
1
2
3
4
5
...